Recordati says goodbye to Giovanni Recordati, 67, chairman and CEO of the pharmaceutical group, after a long illness. Recordati led the company named after his grandfather from 1990 as CEO and from 1999 as Chairman of the Board of Directors since 1999.
Under his guidance, the group experienced a period of expansion which led it to expand into Europe, North America, South America and North Africa and to transform itself into a pharmaceutical company of international standing.
“The passing of Giovanni Recordati – declared Vice Chairman Alberto Recordati -, under whose forward-looking leadership the group has grown significantly, is a painful loss and a very sad moment for the group, its employees and collaborators”. The group's board of directors will meet today at 15.00 pm to deliberate on the attribution of the new offices and powers.
In 2015 the company recorded revenues rising to over one billion and net profit to 198 million euros. In the same period, the stock beat the performance of Piazza Affari, recording a growth of 23%.
The Board of Directors, which met urgently, immediately resolved to appoint Alberto Recordati as Chairman of the Company's Board of Directors and Andrea Recordati as Vice Chairman and Chief Executive Officer. In particular, ad Andrea Recordati, former Chief Operating Officer since 2013 with responsibility for the Group's commercial and production activities, all powers for the ordinary and extraordinary management of the company have been delegated.
